Only show
results from:

Sort results by:

Display preferences
1,036 results sorted by relevancy Results per page:
Antigenics Sells $25 Million of Convertible Senior Secured Notes.
Business Wire; Oct 31, 2006; 700+ Words NEW YORK -- Antigenics Inc. (NASDAQ: AGEN) announced today...the Notes are convertible into Antigenics' common stock at $3.50 per share...interest in a wholly owned subsidiary of Antigenics holding the QS-21 and AG-707...
Antigenics' QS-21 Stimulon(R) Adjuvant Enters Phase 3 Clinical Trial of GlaxoSmithKline's Novel Cancer Immunotherapeutic in Non-Small Cell Lung Cancer.
Business Wire; Jun 5, 2007; 700+ Words NEW YORK -- Antigenics Inc. (NASDAQ: AGEN) today announced that GlaxoSmithKline...GSK's proprietary adjuvant system containing Antigenics' QS-21 Stimulon([R]) adjuvant, for which Antigenics will receive future milestone payments and product...
Antigenics Appoints Roman M. Chicz as Senior Vice President of Research and Preclinical Development.
Business Wire; Jul 26, 2004; 700+ Words NEW YORK -- Antigenics Inc. (NASDAQ:AGEN) today...chairman and CEO of Antigenics. "We look forward to...discovery and development to Antigenics. He most recently held...discovery research at ZYCOS Inc., a company he cofounded...
Antigenics Announces a Negative Vote From the CHMP on Oncophage[R] Marketing Application in Europe.
Business Wire; Oct 21, 2009; 700+ Words LONDON -- Antigenics Inc. (NASDAQ: AGEN) today announced...cell carcinoma (kidney cancer). Antigenics will evaluate its options, including...characterized by a high risk of recurrence. Antigenics believes clinically relevant benefits...
Antigenics to Acquire Aquila Biopharmaceuticals.
PR Newswire; Aug 21, 2000; 700+ Words ...21 /PRNewswire/ -- Antigenics Inc. (Nasdaq: AGEN) and...is 612-332-0923. Antigenics Inc. is engaged in the discovery...visit http://www.antigenics.com. Aquila Biopharmaceuticals, Inc. is a life sciences...
Antigenics Appoints Russell H. Herndon to President and COO.
PR Newswire; Jan 17, 2002; 700+ Words NEW YORK -- Antigenics Inc. announced today that they have appointed its...11690X56353587 Contact: Investors - Linda Lifsey of Antigenics Inc., +1-212-332-2436, llifsey@antigenics.com; or Media - Brad Miles of BMC Communications...
Antigenics Provides Details On GlaxoSmithKline's Pivotal Malaria Vaccine Trial With QS-21 Adjuvant.
Business Wire; Nov 4, 2009; 700+ Words LEXINGTON, Mass. -- Antigenics, Inc. (NASDAQ: AGEN) today indicated...vaccine clinical trial, containing Antigenics' QS-21 Stimulon[R] adjuvant...agreements between the companies, Antigenics will receive payments from GSK...
Antigenics Completes Acquisition of Aronex Pharmaceuticals; Combined Company Expects to File Two New Drug Applications in 2002.
PR Newswire; Jul 12, 2001; 700+ Words NEW YORK, July 12 /PRNewswire/ -- Antigenics Inc. (Nasdaq: AGEN) announced today the...acquisition is expected to be accretive to Antigenics' earnings starting in 2003. Antigenics Inc. is developing treatments for cancer...
Antigenics Reports First Quarter 2006 Financial Results.
Business Wire; May 3, 2006; 700+ Words NEW YORK -- Antigenics Inc. (NASDAQ: AGEN) reported results...s product candidate portfolio, Antigenics incurred reduced research and development...expensing of stock-based compensation, Antigenics incurred a non-cash charge of...
Antigenics Announces New Appointment and Changes in Senior Management.
Business Wire; Nov 3, 2003; 700+ Words ...Jonathan Lewis Leaves the Company Antigenics Inc. (NASDAQ: AGEN) today announced...program and portfolio management. "Antigenics has now reached a critical stage...Armen, PhD, chairman and CEO of Antigenics. "Dr. Gupta's exceptionally...
Antigenics Reports Third Quarter 2006 Financial Results.
Business Wire; Oct 31, 2006; 700+ Words NEW YORK -- Antigenics Inc. (NASDAQ: AGEN) reported results...123R effective January 1, 2006, Antigenics incurred a non-cash charge related...Subsequent to the end of the quarter, Antigenics entered into an agreement to issue...
Antigenics Inc. (NASDAQ: AGEN) Hot Stock on the Move!
M2 Presswire; Jun 17, 2009; 700+ Words ...2009-PennyStockChaser.com: Antigenics Inc. (NASDAQ: AGEN) Hot Stock...Today's news alerts include: Antigenics' QS-21 Adjuvant Enters Pivotal...LEXINGTON, Mass., Jun 17, 2009 -- Antigenics Inc. (NASDAQ: AGEN) today announced...
Antigenics Completes Aquila Merger Creating Preeminent Immunotherapy Company.
PR Newswire; Nov 17, 2000; 700+ Words NEW YORK, Nov. 17 /PRNewswire/ -- Antigenics Inc. (Nasdaq: AGEN) announced today that it has completed...Aquila will now operate as a wholly-owned subsidiary of Antigenics. In connection with the merger, Antigenics will issue...
Antigenics Reports Second Quarter 2003 Financial Results and Recent Highlights.
Business Wire; Jul 23, 2003; 700+ Words ...BUSINESS WIRE)--July 23, 2003 Antigenics Inc. (NASDAQ: AGEN) reported results...Oncophage(R) (HSPPC-96), Antigenics' lead product candidate in Phase...Armen, PhD, chairman and CEO of Antigenics. Recent Highlights -- Antigenics...
Antigenics Appoints Jill M. Forrest as Vice President of Marketing and Sales.
Business Wire; Oct 13, 2005; 700+ Words NEW YORK -- Antigenics Inc. (NASDAQ: AGEN) today announced...Armen, PhD, chairman and CEO of Antigenics. "Jill's experience in launching...oncology." Ms. Forrest brings to Antigenics 20 years of oncology expertise...
Antigenics Appoints Peter Thornton as Chief Financial Officer.
Business Wire; May 25, 2004; 700+ Words ...BUSINESS WIRE)--May 25, 2004 Antigenics Inc. (NASDAQ: AGEN) today announced...qualifications and experience join Antigenics as CFO," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "I have had the opportunity...
Antigenics Reports First Quarter 2004 Financial Results and Recent Highlights.
Business Wire; Apr 20, 2004; 700+ Words ...BUSINESS WIRE)--April 20, 2004 Antigenics Inc. (NASDAQ: AGEN) reported results...Oncophage(R) (HSPPC-96), Antigenics' lead product candidate, and...Armen, PhD, chairman and CEO of Antigenics. Recent Highlights -- In March...
Bruce A. Leicher Joins Antigenics As General Counsel.
PR Newswire; Dec 13, 2005; 700+ Words ...YORK, Dec. 13 /PRNewswire-FirstCall/ -- Antigenics Inc. announced that Bruce A. Leicher has been...Investor Relations, 1-800-962-2436, ir@antigenics.com, both of Antigenics Inc. Web site: http://www.antigenics.com...
Antigenics Reports First Quarter 2007 Financial Results.(Financial report)
Business Wire; May 8, 2007; 700+ Words NEW YORK -- Antigenics Inc. (NASDAQ: AGEN) reported results...000 for the first quarter of 2006. Antigenics incurred research and development...Armen, PhD, chairman and CEO of Antigenics. "Our portfolio of in-house therapeutic...
Antigenics Announces Partial Clinical Hold on Phase III Trials for Kidney Cancer and Melanoma.
Business Wire; Sep 3, 2003; 700+ Words ...Be Held Today at 9:00 am EDT Antigenics Inc. (NASDAQ: AGEN) announced...characterization information from Antigenics. Pending receipt and acceptance...and chief executive officer of Antigenics. "We expect to provide the FDA...
1,036 results: 1 | 2 | 3 | 4 | 5 | Next >>

Find articles, research, and archives